The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma

(2011) P. Moreau et al.   BLOOD

Altered chromatin architecture underlies progressive impairment of the heat shock response in mouse models of Huntington disease

(2011) John Labbadia et al.   JOURNAL OF CLINICAL INVESTIGATION

Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma

(2011) T. Khong et al.   MOLECULAR CANCER THERAPEUTICS

HDACs link the DNA damage response, processing of double-strand breaks and autophagy

(2011) Thomas Robert et al.   NATURE

Untangling the unfolded protein response

(2010) Emma L. Davenport et al.   CELL CYCLE

Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study

(2009) O. Landgren et al.   BLOOD

Caspases and Kinases in a Death Grip

(2009) Manabu Kurokawa et al.   CELL

Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma

(2009) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Multicenter, Phase I, Dose-Escalation Trial of Lenalidomide Plus Bortezomib for Relapsed and Relapsed/Refractory Multiple Myeloma

(2009) Paul G. Richardson et al.   JOURNAL OF CLINICAL ONCOLOGY

International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation

(2009) A Palumbo et al.   LEUKEMIA

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Myeloma Bone Disease: Recent Advances in Biology, Diagnosis, and Treatment

(2009) O. Sezer   ONCOLOGIST

Heat Shock Protein 90 as a Drug Target: Some Like It Hot

(2008) U. Banerji   CLINICAL CANCER RESEARCH

Serum concentrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma

(2008) Martin Kaiser et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Serum concentrations of DKK-1 decrease in patients with multiple myeloma responding to anti-myeloma treatment

(2008) Ulrike Heider et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The potential of proteasome inhibitors in cancer therapy

(2008) Jan Sterz et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Incorporation of the bone marker carboxy-terminal telopeptide of type-1 collagen improves prognostic information of the International Staging System in newly diagnosed symptomatic multiple myeloma

(2008) C Jakob et al.   LEUKEMIA

Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma

(2008) T Stühmer et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interactions of myeloma cells with osteoclasts promote tumour expansion and bone degradation through activation of a complex signalling network and upregulation of cathepsin K, matrix metalloproteinases (MMPs) and urokinase plasminogen activator (uPA)

(2007) Monica Hecht et al.   EXPERIMENTAL CELL RESEARCH